CAR T cells for T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new CAR T-cell treatment for T-cell lymphoma that has come back or hasn't responded to standard treatments. The treatment is designed to target cancer cells that have a protein called CD5 on their surface.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed T-cell lymphoma that is CD5-positive, meaning at least half of the cancer cells have this marker.
- You have already received at least one standard treatment for your lymphoma, and for certain types, you must have tried a drug called brentuximab.
- You have at least one area of disease that can be measured on a scan, or involvement in your bone marrow, bone, or skin.
- You do not have any CD5-positive lymphoma cells circulating in your blood.
- You are not pregnant or breastfeeding, and do not have HIV or an active infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines your own stem cells with special immune cells (CAR T-cells) that target a marker called CD45 on lymphoma cells. It may help people whose lymphoma has not responded to multiple prior therapies.
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
This trial tests a new treatment using your own immune cells, engineered to find and attack cancer cells that have a protein called CD5. It is for people with a type of T-cell lymphoma that has come back or not responded to other treatments.
This trial tests a new type of immune therapy called CAR T cells that are designed to find and attack cancer cells with a CD5 marker. It may be an option for people with T-cell leukemia or lymphoma that has not responded to standard treatments.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
This early-phase trial tests a type of immune-cell therapy (CAR T cells) made using T cells with a CD5-targeting “zipper” to treat certain relapsed T-cell cancers. The goal is to see if the treatment can help shrink or clear the cancer, especially enough to move toward a stem cell transplant plan.
Hear when a new T-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.